BRD4 and squamous cell carcinoma: In addition, an in vivo study provided proof-of-concept for targeting BRD4 with a cell-permeable small molecule (JQ1) in NUT midline carcinoma (NMC), an aggressive squamous carcinoma that develops due to a fusion oncogene (e.g., NUT in frame with BRD4) [229].